Overall, 56% of JQ1 manufacturer total costs were HCV-related and this proportion increased with disease severity (46%, 57%, and 71% for patients with NCD, CC, and ESLD, respectively). A breakdown of total medical costs by disease severity showed that the largest cost components were inpatient costs for those with ESLD and ambulatory costs for those with CC and NCD (Table 4). Inpatient costs comprised 62% of all medical costs for patients with ESLD compared to 38% and 33% for patients with NCD and CC, respectively. All medical cost components were significantly higher for those with ESLD when compared to those with NCD, but only ambulatory costs were significantly higher for those with CC when compared to those with NCD (Table

4). Among patients with ESLD the highest total mean healthcare costs were incurred by patients who underwent OLT ($12,087.12 find more versus $4,393.81 PPPM in patients who had not undergone OLT, P < 0.001; Supporting Table S2) and among those with HCC ($9,378.05 versus $4,254.07 PPPM in patients without ESLD, P < 0.001; Supporting Table S2). Both medical and pharmacy costs were significantly higher in patients with OLT and HCC compared with all other patients with ESLD.

Patients with HCC and PHTN also had significantly higher total healthcare costs than those with HCC and without PHTN ($10,790.51 versus $8,233.95 PPPM, respectively, P = 0.004; Supporting Table S2). The significant difference in total medical costs in this subgroup was associated with significantly higher ambulatory

medical costs, with no significant differences in all other cost components included in the analysis. After adjustment for demographic characteristics, comorbidities, baseline healthcare utilization, and treatments, there were statistically significant differences in incremental cost ratios for all-cause healthcare costs between liver disease severity groups (Table 5). Patients with CC and ESLD were estimated to have total healthcare costs that were 1.40-fold higher (cost ratio 1.40; 95% CI 1.31-1.49) and 3.33-fold higher (cost ratio 3.33; 95% CI 3.12-3.56), respectively, than those for patients with NCD. The estimated cost ratios were also significantly higher for both medical costs and pharmacy costs for patients with CC and ESLD when compared with patients with NCD (Table 5). Other factors that MCE公司 were found to be statistically significantly associated with healthcare costs in this model included age 18-34 years (cost ratio 1.40; 95% CI 1.16-1.69) and age >65 years (cost ratio 0.72; 95% CI 0.62-0.83) as compared with the reference category of 35-44 years, male gender (cost ratio 1.164 versus female gender; 95% CI 1.11-1.22), an index year of 2010 relative to 2003 (cost ratio 1.270; 95% CI 1.10-1.47), baseline Charlson comorbidity score (cost ratio 1.08; 95% CI 1.05-1.10), HIV coinfection (cost ratio 1.75; 95% CI 1.49-2.05), a diagnosis of cancer (other than HCC, superficial skin cancer or cancer in situ) (cost ratio 1.13; 95% CI 1.06-1.